RS
Therapeutic Areas
Click Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CT-152 (Rejoyn™) | Major Depressive Disorder (adjunct to antidepressant medication) | Phase 3 |
| CT-132 | Episodic Migraine | Phase 3 |
| CT-155 | Negative Symptoms of Schizophrenia | Phase 3 |
| Unnamed Breast Cancer Program | Breast Cancer | Pilot/Phase 2 |
Leadership Team at Click Therapeutics
DB
David Benshoof Klein
Founder & CEO
AS
Austin Speier
Chief Strategy Officer
SL
Steven Lee
Director, Strategy